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Zusammenfassung
In den letzten 10 Jahren hat das Verfahren der molekula-
ren Charakterisierung durch die Schaffung einer neuen, 
auf der Expression von sogenannten «intrinsischen 
Genen» basierenden Taxonomie unser Verständnis von 
invasiven Mammakarzinomen grundlegend verändert. 
Durch hierarchische Cluster-Analysen an mittels Micro-
arrays bestimmten Genexpressionsprofilen konnten dis-
tinkte Subgruppen des Mammakarzinoms definiert wer-
den (luminaler Typ A/B, HER2-angereicherter Typ, Basal-
zell-Typ). Seit der bahnbrechenden Arbeit durch Perou et 
al. wurde das Konzept der intrinsischen Subtypen des 
Mammakarzinoms von mehreren Arbeitsgruppen bestä-
tigt und erweitert. Weitere Studien zeigten wesentliche 
Unterschiede zwischen den intrinsischen Subgruppen 
bezüglich des klinischen Verlaufs und des Ansprechens 
auf Chemotherapie. Die neue, auf Genexpression basie-
rende Taxonomie der invasiven Mammakarzinome 
wurde von der Wissenschaftsgemeinde begeistert ange-
nommen und als Durchbruch auf dem Weg zur individu-
alisierten Therapie gefeiert. Dennoch ist eine Validierung 
der auf Gensignaturen basierenden Untersuchungen in 
prospektiven Untersuchungen erforderlich, bevor diese 
Technologien im klinischen Alltag eingesetzt werden 
können. Diese Übersichtsarbeit befasst sich mit den in-
trinsischen Subtypen des invasiven Mammakarzinoms, 
den hiermit assoziierten klinischen Implikationen wie 
auch mit der Methodik der molekularen Charakterisie-
rung und der Frage, ob die intrinsischen Subtypen auch 
mittels Immunhistochemie identifiziert werden können.
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Summary
Molecular profiling has fundamentally changed our 
understanding of breast cancer in the last 10 years, by 
creating a new taxonomy of breast cancers based on 
the expression patterns of so-called ‘intrinsic genes’. 
Hierarchical clustering analyses performed on micro-
array-based gene expression profiles of breast cancers 
defined distinct breast cancer subgroups (luminal type 
A/B, HER2-enriched type, basal-like type). Since the 
initial landmark study by Perou et al., the concept of 
intrinsic breast cancer subtypes has been corroborated 
and expanded by several independent research groups. 
Further studies revealed individual properties of the 
intrinsic subgroups regarding the clinical course and the 
responsiveness to chemotherapy. The new gene expres-
sion profile-based taxonomy of breast cancer has been 
enthusiastically embraced by the scientific community 
and hailed as a major breakthrough on the way to indi-
vidually tailored therapies. However, validation of the 
gene signatures in prospective studies is necessary be-
fore accepting these new technologies in daily clinical 
practice. In this review, the current data regarding the 
intrinsic subtypes and the associated clinical implica-
tions as well as the methodology of molecular profiling 
and possible use of immunohistochemistry in identifying 
intrinsic subtypes are discussed.
*These authors contributed equally to this work.
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Molecular Subtypes, Mammary Development and 
Breast Cancer Evolution
Perou et al. [4] suggested that the intrinsic subtypes might 
reflect the different molecular features of mammary epithelial 
biology. This hypothesis was taken further by Prat and Perou 
[5] who suggested that the majority of invasive breast cancers 
could be assigned to different developmental points of the 
mammary epithelium. However, detailed analyses of gene 
mutation profiles amongst intrinsic subtypes revealed distinct 
gene mutation patterns for the different intrinsic subtypes, 
with a high index of p53 mutations in basal-like carcinomas 
[6–8]. These findings suggest that in breast cancer the molecu-
lar subtype of carcinoma might either be determined by the 
cell of origin or different genomic alterations, or possibly a 
combination of both.
Luminal Intrinsic Subtype
The defining molecular feature of luminal-type breast cancer 
is the expression of the ER [4]. Luminal-type breast cancer 
carries the best prognosis of all intrinsic subtypes [9] and 
responds to endocrine therapy [3]. Interestingly, invasive lob-
ular breast cancer (ILC) overwhelmingly is classified as lumi-
nal type [10, 11]. Generally, ILC and low-grade IDC are sub-
sumed as low-grade breast neoplasia family [12]. Molecular 
profiling seems to corroborate this concept. While basal-like 
and HER2-enriched breast cancers often respond well to 
neoadjuvant chemotherapy, the luminal subtypes show only 
limited chemosensitivity [13, 14]. Sorlie et al. [9] were the first 
to suggest a subdivision of luminal-type carcinoma into at 
least 2 distinct subgroups with characteristic molecular pro-
files and different prognoses, namely luminal type A breast 
cancer (fig. 1) and luminal type B cancer (fig. 2). The major 
difference between luminal A and luminal B breast cancers 
is the degree of proliferation and the HER2 expression signa-
ture, which is more pronounced in luminal B-type breast can-
cers [15, 16]. The distinction between luminal A and B carci-
nomas is of high clinical interest as luminal A-type breast 
carcinomas seem to be at a lower risk for relapse [13, 17] and 
luminal B-type breast carcinoma generally carries a worse 
prognosis but responds only slightly better to chemotherapy 
than luminal A-type carcinoma [18]. However, proliferation 
in ER+ carcinomas is a continuum, which makes a separation 
of luminal subgroups on the basis of proliferation – be it on an 
immunohistochemical level or on a molecular level – arbitrary 
and defining a cut-off difficult [13, 19, 20].
Basal-Like Intrinsic Subtype
The basal-like subtype of breast cancer (fig. 3) is character-
ized by the expression of cytokeratins, which are typically 
expressed in the basal cells of normal mammary gland epi-
thelium, and by a very high expression of the proliferation 
cluster. It makes up approximately 15% of invasive breast 
cancers [21–23]. There is a striking prevalence of this mole-
Introduction
Invasive breast carcinoma is the most common cancer of 
women and has been categorized by histomorphological crite-
ria into invasive ductal carcinoma (IDC), invasive lobular 
carcinoma (ILC), and other less common subtypes [1]. In 
most institutes, a 3-tiered grading scheme regarding growth 
pattern, nuclear grade and proliferative activity is used to 
further subdivide these subtypes [2]. Additionally, immuno-
histochemical analysis of estrogen receptor (ER), progester-
one receptor (PR) and HER2 expression is carried out to 
determine if patients qualify for adjuvant therapy.
In recent years, DNA microarrays have been used to classify 
invasive breast carcinomas independently of histomorphologi-
cal and immunohistochemical criteria. DNA microarrays rep-
resent a technology in which RNA is extracted from a tumor 
sample, transcribed into cDNA or cRNA and hybridized to 
microarray spots coated with DNA/RNA sequences represent-
ing distinct genes. With the aid of fluorescence labeling, the 
gene expression levels are determined in relation to a normal 
reference. With the advent of the DNA micro array technique, 
the determination of the expression levels of thousands of 
genes in one single tumor specimen has become possible [3].
Discovery of Intrinsic Subtypes in Breast Cancer:  
The Seminal Work
In their seminal work, Perou et al. [4] employed DNA micro-
arrays for the investigation of the molecular profile of a col-
lective of 65 surgical breast tumor specimens from 42 individ-
ual patients. A central concept of this study was that tumors 
could be characterized by the up- or down-regulation of spe-
cial sets of genes, so-called ‘intrinsic genes’. Intrinsic genes 
were defined as genes with significantly greater variation in 
expression between different tumors than between paired 
samples from the same tumor. On the basis of this algorithm, 
496 gene probes representing an ‘intrinsic gene list’ were se-
lected from an early microarray encompassing 8102 genes.
Numerous clusters representing genes associated with dif-
ferent breast cell types/functions were discovered. With the 
aid of hierarchical clustering analyses, 4 distinct molecular 
subgroups of invasive breast cancer were described: ER+/ 
luminal-like, basal-like, HER2 enriched and normal breast-
like. By defining these so-called ‘intrinsic’ subtypes, the ground-
work for a new molecular taxonomy was laid [4]. Of note, it is 
highly probable that the normal breast-like subtype is an arti-
fact caused by sampling errors. This point will be discussed 
further in the section ‘Critique of Methodology’. Another im-
portant piece of information derived from the experiment by 
Perou et al. is that the group of ER-negative breast cancers is 
made up of at least two biologically distinct subtypes of tu-
mors (basal-like, HER2 enriched), which are now understood 
as distinct diseases with different treatment options.
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to 25% of breast cancers are HER2 positive as defined by im-
munohistochemistry and fluorescence in situ hybridization/
chromogenic in situ hybridization (FISH/CISH) [30]. It is 
intriguing that not all breast cancers defined as HER2 positive 
by immunohistochemistry are classified as HER2 enriched by 
molecular profiling. At the same time, not all intrinsic HER2 
enriched tumors are diagnosed as HER2 amplified by immu-
nohistochemistry or in situ hybridization [13, 31, 32]. Studies 
are needed to ascertain whether the molecular subtype HER2 
enriched may profit from trastuzumab therapy in cases when 
HER2 amplification cannot be proven with conventional 
methods. Clinical experience demonstrates clearly that the 
collective of HER2-positive patients as defined by immuno-
histochemistry is a heterogeneous group, in particular regard-
ing the response to HER2 blockers. It is well known that a 
significant number of patients with HER2-positive breast can-
cers possess a primary trastuzumab resistance or develop a 
secondary resistance to trastuzumab within 1 year [33]. Fur-
thermore, it has been suggested that some patients with 
HER2-positive breast cancer might in fact even suffer a prog-
nostic disadvantage from chemotherapy and trastuzumab 
therapy [34]. As of now, it is unclear whether the molecular 
subtyping with definition of the HER2-enriched intrinsic sub-
type performs better than immunohistochemistry or FISH/
CISH in the clinical context. Extensive studies will be needed 
to reliably identify the patients who will profit from a HER2-
targeting therapy, and hopes are high that molecular profiling 
will provide the solution of this therapeutical riddle.
Potential New Intrinsic Subtypes: Claudin-Low Subtype and 
Apocrine Subtype
Current data indicate that additional molecular subtypes will 
need to be incorporated into the molecular profiling system in 
order to render the biological picture more complete.
cular subtype in premenopausal African-American women 
[22], which may partially explain the poor outcomes charac-
teristic of this patient group. Interestingly, BRCA1 mutation-
associated breast carcinomas as a group strongly resemble 
sporadic basal-like tumors and might be regarded as a special 
subgroup in this intrinsic subtype [4, 24, 25]. It has been shown 
that, among the intrinsic subtypes as determined by molecular 
profiling, the basal-like subtype and the HER2-enriched sub-
type treated with trastuzumab showed the highest response 
rates to neoadjuvant chemotherapy [13, 14].
HER2-Enriched Intrinsic Subtype
The HER2-enriched subtype of breast cancer (fig. 4) is de-
fined by overexpression of the HER2/neu gene and a lack of 
expression of genes characteristic of the luminal subtypes. Up 
Fig. 1. Example of luminal A-type carcinoma: Well differentiated IDC 
(grade 1) with nuclear ER and PR expression in over 90% of tumor cells, 
HER2/neu negativity and a proliferative index of < 14% of tumor cells.
Fig. 2. Example of luminal B-type carcinoma: Moderately differentiated 
IDC (grade 2) with nuclear ER and PR expression in over 90% of tumor 
cells, HER2/neu expression and a proliferative index of > 14% of tumor cells.
Fig. 3. Example of a basal-type carcinoma: Poorly differentiated 
invasive carcinoma with negativity for ER and PR and negativity for 
HER2/neu and expression of CK5 and EGFR.
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whether the intrinsic subtypes can be reliably identified by 
histomorphology alone or through a standard immunohisto-
chemistry panel.
Histomorphological criteria can provide useful clues to the 
diagnosis of the different molecular subtypes, e.g. luminal 
tumors usually show a good or moderate differentiation with 
tubule formation whereas basal-like carcinomas reveal poor 
differentiation with central necrosis and prominent lymphoid 
infiltrates. However, the discriminative power of histomor-
phology is very limited regarding intrinsic subtypes.
Regarding immunohistochemistry, different study groups 
have tried to emulate molecular subtyping using a standard 
immunohistochemistry surrogate panel encompassing ER, 
PR, HER2/neu and Ki67. Generally, the luminal subtype can 
be identified by immunohistochemical expression of the ER 
or the PR. As described above, luminal B carcinomas are 
characterized by additional HER2 expression and/or higher 
proliferation. Cheang et al. [15] have shown that the differen-
tiation between luminal A and B tumors with a sensitivity of 
77% and a specificity of 78% is possible using a Ki67 cut-off 
of 14%. Recent studies have demonstrated that the combina-
tion of ER, HER2 and PR negativity and EGFR and CK5/6 
positivity accurately identifies basal-like tumors from gene 
microarray data with 100% specificity and 76% sensitivity 
[23]. However, it has been shown that 9% of immunohisto-
chemically triple-negative tumors were assigned to the HER2-
enriched subtype on a molecular level, whereas 5% and 6% 
showed a molecular pattern corresponding to luminal A and 
B, respectively [28]. This heterogeneity at the molecular level 
of tumors with a similar immunohistochemical profile was 
corroborated by other studies, which showed that virtually all 
intrinsic subtypes are represented in the different clinico-
pathological breast carcinoma categories [13, 35]. This data 
suggests that the intrinsic subtypes are closely, but not fully 
and accurately represented by the standard immunohisto-
chemical markers used in clinical practice today.
Does Genetic Profiling Provide Additional  
Prognostic and Predictive Information beyond  
Standard Clinico-Pathological Parameters?
The vast individualized data set generated by the molecular 
profiling of breast carcinoma has very soon led to the 
question whether the knowledge of the molecular profile of 
individual breast carcinomas also conveys significant prognos-
tic and predictive information.
The advent of gene profiling has given a significant boost 
to the efforts of pinpointing those patients with ER+ breast 
carcinoma who will – with high probability – profit from adju-
vant chemotherapy. At the same time, it is of major medical 
and financial interest to identify patients with a low risk of re-
currence who could be spared the toxicity of chemotherapy. 
To this end, several working groups have devised molecular 
Currently, the molecular subtype ‘claudin-low’ is moving 
into the center of the molecular researchers’ attention. Neve 
et al. [26] reported a specific subtype in breast cancer 
cell lines that showed stem cell properties and was named 
‘basal B’ subtype. The claudin-low subtype is characterized 
by a low expression of genes involved in tight junctions 
and cell-cell adhesion [27, 28]. Tumors of the claudin-low 
subtype resemble the basal-like subtype insofar as they show 
negativity for ER, PR and HER2. However, claudin-low 
tumors lack classical basal-like markers like cytokeratins 
5/6 (CK5/6) and epidermal growth factor receptor (EGFR). 
According to Prat et al. [28], the claudin-low subtype repre-
sents 12–14% of the triple-negative carcinomas. As of now, 
data are lacking regarding the clinical implications of this new 
subtype. It is furthermore unclear whether the claudin-low 
subtype should be regarded as a distinct molecular and clini-
cal subtype or rather as a component of the basal-like intrinsic 
subtype.
Another distinct molecular subgroup of breast tumors is 
characterized by ER negativity and androgen receptor (AR) 
positivity as well as by an apocrine morphology. The authors 
contend that tumors of the apocrine subtype may make up a 
substantial part of ER– tumors outside the basal subtype [29].
Can Intrinsic Molecular Subtypes Be Reliably  
Identified by Immunohistochemistry or Even 
Histomorphology?
Molecular profiling of cancer represents a time-consuming 
and expensive method and requires unfixed tumor tissue 
snap-frozen under standardized conditions immediately after 
surgery. Therefore, a question of great clinical relevance is 
Fig. 4. Example of HER2/neu-enriched carcinoma: Poorly differentiated 
invasive micropapillary carcinoma with ER and PR negativity, strong 
membraneous expression of HER2/neu in > 30% of tumor cells and a 
proliferative index of > 14% of tumor cells.
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represent not only the tumor cells but also the peritumoral 
reaction and the host tissue. It seems probable that the sub-
type of normal-like breast carcinoma is an artifact of gene 
expression profiling, caused by the analysis of samples with a 
high content of normal breast epithelial cells and stromal cells 
[13, 32]. Furthermore, in the case of microinvasive carcinoma 
with extensive DCIS, there is no safe way of guaranteeing that 
the invasive carcinoma and not the in situ component are 
analyzed.
Beyond the level of methodology, the rather small sample 
sizes upon which the groundbreaking works of Perou and 
Sorlie were based were regarded with some uneasiness. In-
deed, in his seminal work describing ‘molecular portraits of 
human breast tumors’, Perou analyzed a set of 65 surgical 
specimens derived from 42 different individuals [4]. In the 
following 2 publications by the Stanford group that further 
outlined the concept of molecular profiling of breast carci-
noma, Sorlie et al. based their analyses on 78 and 115 breast 
carcinomas, respectively [9, 24]. Considering that in these 
studies a whole new molecular profile-based taxonomy of 
breast carcinomas was developed, a greater sample size would 
have validated the new concept with greater statistical power.
As molecular profiling is often hailed as a largely unbiased 
analysis tool that allows scientists to avoid the subjectivity of 
immunohistochemistry and histopathological grading, it is 
often forgotten that the hierarchical clustering method, far 
from being a completely automated analysis, is a method that 
requires the input of a human observer for the final interpre-
tation of the data. In a test encompassing the 5 major intrinsic 
gene lists, Mackay et al. [47] demonstrated that none of the 
classification systems produced almost perfect interobserver 
agreement. The best interobserver agreement was docu-
mented for basal-type and HER2-enriched breast carcinomas, 
whereas poor interobserver agreement was found for luminal-
type breast carcinomas.
It is also important to bear in mind that the analyzing tool 
of hierarchical clustering can only be applied retrospectively, 
to adequately sized collectives. The classical microarray-based 
hierarchical clustering method is therefore not suitable for 
assigning intrinsic subtypes to particular samples as the den-
drogram changes with each additionally included sample. To 
circumvent this particular problem, single sample predictors 
(SSPs) have been devised [13, 24, 40]. SSPs are based on the 
median expression patterns of the different intrinsic subtypes 
(i.e. centroids). The SSP allows for any given sample to be as-
signed to the intrinsic subtype most similar in its molecular 
profile. However, the reliability of SSPs has been discussed 
controversially. While some groups have reported reliable 
and reproducible intrinsic subgroup assignments through 
SSPs [40], others have questioned the validity of this method 
and claimed that only basal-like breast carcinomas were safely 
identified by this method [32]. Further studies are needed to 
ascertain whether SSPs represent a valid method for molecu-
lar subtyping.
signature-based tests to better judge the risk of recurrence of 
ER-positive, lymph node-negative breast carcinomas. 
Amongst these tests, the most well known are the 70-gene 
good versus poor outcome model (‘Mammaprint’; [36]), the 
‘wound response model’ [37, 38], the recurrence score model 
(‘OncotypeDX’; [39]), the intrinsic subtype model [4, 9, 24, 
40] and the two gene ratio model [41]. Skepticism was induced 
by the fact that, although these tests were designed to be ap-
plied to the same clinical problem, only a small gene overlap 
exists between these tests [42]. However, when tested against 
the same data set, all tests but one (the two gene ratio model) 
showed similar prognostic values [17].
It has been argued that only high-throughput technologies 
are able to fully capture the biological diversity of breast car-
cinoma. In this context it needs to be mentioned that the pro-
liferation (signature) is the mainstay in all classifiers to divide 
ER+, lymph node-negative tumors into subgroups with differ-
ent prognosis [43]. In particular, OncotypeDX relies heavily 
on proliferation-related genes [20]. This raises the question 
whether immunohistochemical or even histomorphological 
parameters might not be equally efficient as surrogates for 
prognosis and prediction instead of costly molecular assays. 
However, until today, results of prospective randomized stud-
ies addressing the question whether better prognostic or pre-
dictive information can be achieved using molecular profiling 
in comparison to the classical clinico-pathological data sets 
are lacking. Ongoing prospective studies like the Mindact 
study will hopefully clarify to which extent molecular profiling 
provides additional prognostic and predictive information.
Molecular Profiling – a Critique of Methodology
Molecular profiling has been enthusiastically received as an 
exciting new technology by the scientific community. How-
ever, there were also some calls for caution which criticized 
the over-enthusiastic and uncritical embracing of a new 
method still lacking rigorous validation [44, 45]. First of all, 
the new molecular taxonomy was based on findings derived 
from different microarray platforms. To address the question 
of reproducibility of microarray technology, the US Food and 
Drug Administration (FDA) instigated the Microarray Qual-
ity Control (MAQC) project. The data collected in this exten-
sive study showed that microarray measurements are highly 
reproducible within and across different microarray plat-
forms. As a consequence, the FDA judged the microarray 
technology sufficiently reliable for clinical and regulatory pur-
poses [46]. However, it needs to be pointed out that different 
profiling gene sets cannot be transferred from one microarray 
platform to another without extensive modification. As a con-
sequence, the results of different microarray platforms cannot 
be directly compared. Another point of critique concerns the 
samples used for microarray technologies. As the tissue sam-
ples are not microdissected before analysis, the gene profiles 
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creases, so will our understanding of breast cancer biology. 
However, the uncritical acceptance of new technologies may 
generate massive amounts of insufficiently validated data. In 
order to stay on top of this data flood, it is absolutely neces-
sary to rigorously enforce standardization and validation of 
the new technologies. Furthermore, molecular profiling should 
be regarded as a component of the whole clinico-pathological 
picture and not be aggressively marketed as a superior substi-
tute to the diagnostic, prognostic and predictive methods cur-
rently in use. Rather than furthering the cause of molecular 
profiling, the hybris of calling pathology unsophisticated and 
subjective [48], together with the rather spectacular claim that 
microarrays will be the key to curing all human disease until 
2050 [49], serve as a provocation not only to surgical patholo-
gists. Retaliation has occurred in the form of growing criti-
cism, cumulating in one expert in biomarkers claiming that it is 
statistically and mathematically possible to prove that any given 
gene affects survival ‘even if it does not’ [44]. In the interest of 
science and patient care alike it is time to take the competitive 
edge out of the discussion regarding molecular profiling.
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It must be noted that, while the technique of RNA-based 
molecular subtyping allows fascinating insights into the 
molecular properties of breast cancer, it is not (yet) a very 
good tool for assessing individual samples.
Despite the scientific and medial hype, we are therefore 
not yet at a point where this new technology has a relevant 
impact on day-to-day clinical practice.
Conclusions
The criticism inherent in the stringent validation of molecular 
profiling should not be misinterpreted as a rejection of an 
exciting new technology. Gene expression profiling carries an 
enormous potential and has taken us some way towards indi-
vidualized therapy. The massive potential of this powerful 
high-throughput technology which allows investigators to 
better capture the molecular diversity of cancer cannot be 
overestimated, especially as the high-throughput technologies 
are continually being improved and expanded. It is to be ex-
pected that newer methods analyzing additional epigenetic 
factors such as non-coding RNAs and alternative splicing will 
complement and enrich molecular profiling in the future. High-
throughput technologies have opened the way to the acquisi-
tion of unprecedented amounts of data regarding individual 
tumors. As our technical prowess in molecular profiling in-
acterization of histological special types. J Pathol 
2008;216:141–150.
12 Abdel-Fatah TM, Powe DG, Hodi Z, Reis-Filho JS, 
Lee AH, Ellis IO: Morphologic and molecular evo-
lutionary pathways of low nuclear grade invasive 
breast cancers and their putative precursor lesions: 
Further evidence to support the concept of low 
nuclear grade breast neoplasia family. Am J Surg 
Pathol 2008;32:513–523.
13 Parker JS, Mullins M, Cheang MC, Leung S, 
Voduc D, Vickery T, Davies S, Fauron C, He X, 
Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, 
Marron JS, Nobel AB, Mardis E, Nielsen TO, 
Ellis MJ, Perou CM, Bernard PS: Supervised 
risk predictor of breast cancer based on intrinsic 
subtypes. J Clin Oncol 2009;27:1160–1167.
14 Rouzier R, Perou CM, Symmans WF, Ibrahim N, 
Cristofanilli M, Anderson K, Hess KR, Stec J, 
Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, 
Ross JS, Hortobagyi GN, Pusztai L: Breast 
cancer molecular subtypes respond differently 
to preoperative chemotherapy. Clin Cancer Res 
2005;11:5678–5685.
15 Cheang MC, Chia SK, Voduc D, Gao D, Leung S, 
Snider J, Watson M, Davies S, Bernard PS, 
Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 
index, HER2 status, and prognosis of patients 
with luminal B breast cancer. J Natl Cancer Inst 
2009;101:736–750.
16 Nielsen TO, Parker JS, Leung S, Voduc D, 
Ebbert M, Vickery T, Davies SR, Snider J, 
Stijleman IJ, Reed J, Cheang MC, Mardis ER, 
Perou CM, Bernard PS, Ellis MJ: A compari-
son of PAM50 intrinsic subtyping with immuno-
 1 Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, 
Tavassoli FA, Eusebi V, Peterse JL, Mukai K, 
Tabar L, Jacquemier J, Cornelisse CJ, Sasco AJ, 
Kaaks R, Pisani P, Goldgar DE, Devilee P, 
Cleton-Jansen MJ, Borresen-Dale AL, van’t Veer L, 
Sapino A: Invasive breast carcinoma; in Tavassoli FA, 
Devilee P (eds): Tumours of the Breast and 
Female Genital Organs. Lyon, IARC Press, 2003, 
pp 13–59.
 2 Elston CW, Ellis IO: Pathological prognostic fac-
tors in breast cancer. I. The value of histological 
grade in breast cancer: Experience from a large 
study with long-term follow-up. Histopathology 
1991;19:403–410.
 3 Peppercorn J, Perou CM, Carey LA: Molecular 
subtypes in breast cancer evaluation and man-
agement: Divide and conquer. Cancer Invest 
2008;26:1–10.
 4 Perou CM, Sorlie T, Eisen MB, van de Rijn M, 
Jeffrey SS, Rees CA, Pollack JR, Ross DT, 
Johnsen H, Akslen LA, Fluge O, Pergamen-
schikov A, Williams C, Zhu SX, Lonning PE, 
Borresen-Dale AL, Brown PO, Botstein D: 
Molecular portraits of human breast tumours. 
Nature 2000;406:747–752.
 5 Prat A, Perou CM: Mammary development meets 
cancer genomics. Nat Med 2009;15:842–844.
 6 Hollestelle A, Nagel JH, Smid M, Lam S, 
Elstrodt F, Wasielewski M, Ng SS, French PJ, 
Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, 
Ten Hagen TL, de Leeuw BH, Zwarthoff EC, 
Teunisse A, van der Spek PJ, Klijn JG, 
Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, 
den Bakker MA, Foekens JA, Martens JW, 
Schutte M: Distinct gene mutation profiles among 
luminal-type and basal-type breast cancer cell lines. 
Breast Cancer Res Treat 2010;121:53–64.
 7 Hu X, Stern HM, Ge L, O’Brien C, Haydu L, 
Honchell CD, Haverty PM, Peters BA, Wu TD, 
Amler LC, Chant J, Stokoe D, Lackner MR, 
Cavet G: Genetic alterations and oncogenic path-
ways associated with breast cancer subtypes. 
Mol Cancer Res 2009;7:511–522.
 8 Langerod A, Zhao H, Borgan O, Nesland JM, 
Bukholm IR, Ikdahl T, Karesen R, Borresen-Dale 
AL, Jeffrey SS: Tp53 mutation status and gene ex-
pression profiles are powerful prognostic markers 
of breast cancer. Breast Cancer Res 2007;9:R30.
 9 Sorlie T, Perou CM, Tibshirani R, Aas T, 
Geisler S, Johnsen H, Hastie T, Eisen MB, 
van de Rijn M, Jeffrey SS, Thorsen T, Quist H, 
Matese JC, Brown PO, Botstein D, Eystein 
Lonning P, Borresen-Dale AL: Gene expression 
patterns of breast carcinomas distinguish tumor 
subclasses with clinical implications. Proc Natl 
Acad Sci USA 2001;98:10869–10874.
10 Weigelt B, Geyer FC, Natrajan R, Lopez- 
Garcia MA, Ahmad AS, Savage K, Kreike B, 
Reis-Filho JS: The molecular underpinning of 
lobular histological growth pattern: A genome-
wide transcriptomic analysis of invasive lobular 
carcinomas and grade- and molecular subtype-
matched invasive ductal carcinomas of no special 
type. J Pathol 2010;220:45–57.
11 Weigelt B, Horlings HM, Kreike B, Hayes MM, 
Hauptmann M, Wessels LF, de Jong D, Van de 
Vijver MJ, Van’t Veer LJ, Peterse JL: Refinement 
of breast cancer classification by molecular char-
References
264 Breast Care 2011;6:258–264 Strehl/Wachter/Fasching/Beckmann/Hartmann
histochemistry and clinical prognostic factors 
in tamoxifen-treated estrogen receptor-positive 
breast cancer. Clin Cancer Res 2010;16:5222–5232.
17 Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, 
Nobel AB, van’t Veer LJ, Perou CM: Concordance 
among gene-expression-based predictors for breast 
cancer. N Engl J Med 2006;355:560–569.
18 Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, 
Collichio F, Ollila DW, Sartor CI, Graham ML, 
Perou CM: The triple negative paradox: Primary 
tumor chemosensitivity of breast cancer subtypes. 
Clin Cancer Res 2007;13:2329–2334.
19 Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, 
Larsimont D, Bontempi G, Delorenzi M, Piccart M, 
Sotiriou C: Biological processes associated with 
breast cancer clinical outcome depend on the mole-
cular subtypes. Clin Cancer Res 2008;14:5158–5165.
20 Wirapati P, Sotiriou C, Kunkel S, Farmer P, 
Pradervand S, Haibe-Kains B, Desmedt C, 
Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, 
Piccart M, Delorenzi M: Meta-analysis of gene 
expression profiles in breast cancer: Toward a 
unified understanding of breast cancer subtyp-
ing and prognosis signatures. Breast Cancer Res 
2008;10:R65.
21 Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, 
Blamey RW, Robertson JF, Nicholson RI, 
Ellis IO: Expression of luminal and basal cyto-
keratins in human breast carcinoma. J Pathol 
2004;203:661–671.
22 Carey LA, Perou CM, Livasy CA, Dressler LG, 
Cowan D, Conway K, Karaca G, Troester MA, 
Tse CK, Edmiston S, Deming SL, Geradts J, 
Cheang MC, Nielsen TO, Moorman PG, Earp 
HS, Millikan RC: Race, breast cancer subtypes, 
and survival in the Carolina Breast Cancer Study. 
JAMA 2006;295:2492–2502.
23 Nielsen TO, Hsu FD, Jensen K, Cheang M, 
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, 
Cowan D, Dressler L, Akslen LA, Ragaz J, 
Gown AM, Gilks CB, van de Rijn M, Perou CM: 
Immunohistochemical and clinical characterization 
of the basal-like subtype of invasive breast carci-
noma. Clin Cancer Res 2004;10:5367–5374.
24 Sorlie T, Tibshirani R, Parker J, Hastie T, 
Marron JS, Nobel A, Deng S, Johnsen H, 
Pesich R, Geisler S, Demeter J, Perou CM, 
Lonning PE, Brown PO, Borresen-Dale AL, 
Botstein D: Repeated observation of breast tumor 
subtypes in independent gene expression data sets. 
Proc Natl Acad Sci USA 2003;100:8418–8423.
25 Turner N, Tutt A, Ashworth A: Hallmarks of 
‘BRCAness’ in sporadic cancers. Nat Rev Cancer 
2004;4:814–819.
26 Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, 
Fevr T, Clark L, Bayani N, Coppe JP, Tong F, 
Speed T, Spellman PT, DeVries S, Lapuk A, 
Wang NJ, Kuo WL, Stilwell JL, Pinkel D, 
Albertson DG, Waldman FM, McCormick F, 
Dickson RB, Johnson MD, Lippman M, Ethier S, 
Gazdar A, Gray JW: A collection of breast can-
cer cell lines for the study of functionally distinct 
cancer subtypes. Cancer Cell 2006;10:515–527.
27 Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, 
Usary J, Hu Z, Rasmussen KE, Jones LP, 
Assefnia S, Chandrasekharan S, Backlund MG, 
Yin Y, Khramtsov AI, Bastein R, Quackenbush J, 
Glazer RI, Brown PH, Green JE, Kopelovich L, 
Furth PA, Palazzo JP, Olopade OI, Bernard PS, 
Churchill GA, Van Dyke T, Perou CM: Identifi-
cation of conserved gene expression features be-
tween murine mammary carcinoma models and 
human breast tumors. Genome Biol 2007;8:R76.
28 Prat A, Parker JS, Karginova O, Fan C, Livasy C, 
Herschkowitz JI, He X, Perou CM: Phenotypic 
and molecular characterization of the claudin-low 
intrinsic subtype of breast cancer. Breast Cancer 
Res 2010;12:R68.
29 Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, 
Fumoleau P, Larsimont D, Macgrogan G, Bergh J, 
Cameron D, Goldstein D, Duss S, Nicoulaz AL, 
Brisken C, Fiche M, Delorenzi M, Iggo R: Identi-
fication of molecular apocrine breast tumours by 
microarray analysis. Oncogene 2005;24:4660–4671.
30 Slamon DJ: Proto-oncogenes and human cancers. 
N Engl J Med 1987;317:955–957.
31 de Ronde JJ, Hannemann J, Halfwerk H, Mulder L, 
Straver ME, Vrancken Peeters MJ, Wesseling J, 
van de Vijver M, Wessels LF, Rodenhuis S: 
Concordance of clinical and molecular breast 
cancer subtyping in the context of preoperative 
chemotherapy response. Breast Cancer Res Treat 
2010;119:119–126.
32 Weigelt B, Mackay A, A’Hern R, Natrajan R, 
Tan DS, Dowsett M, Ashworth A, Reis-Filho JS: 
Breast cancer molecular profiling with single 
sample predictors: A retrospective analysis. Lancet 
Oncol 2010;11:339–349.
33 Hubalek M, Brunner C, Mattha K, Marth C: 
Resistance to HER2-targeted therapy: Mecha-
nisms of trastuzumab resistance and possible 
strategies to overcome unresponsiveness to treat-
ment. Wien Med Wochenschr 2010;160:506–512.
34 Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, 
Sgroi D, Ryan PD, Come SE, Burstein HJ, 
Lesnikoski BA, Kamma M, Friedman PN, 
Gelman R, Iglehart JD, Winer EP: Predictors 
of resistance to preoperative trastuzumab and 
vinorelbine for HER2-positive early breast cancer. 
Clin Cancer Res 2007;13:1198–1207.
35 Prat A, Perou CM: Deconstructing the molecular 
portraits of breast cancer. Mol Oncol 2010;5:5–23.
36 van’t Veer LJ, Dai H, van de Vijver MJ, He YD, 
Hart AA, Mao M, Peterse HL, van der Kooy K, 
Marton MJ, Witteveen AT, Schreiber GJ, 
Kerkhoven RM, Roberts C, Linsley PS, 
Bernards R, Friend SH: Gene expression profiling 
predicts clinical outcome of breast cancer. Nature 
2002;415:530–536.
37 Chang HY, Nuyten DS, Sneddon JB, Hastie T, 
Tibshirani R, Sorlie T, Dai H, He YD, van’t Veer LJ, 
Bartelink H, van de Rijn M, Brown PO, van de 
Vijver MJ: Robustness, scalability, and integration 
of a wound-response gene expression signature in 
predicting breast cancer survival. Proc Natl Acad 
Sci USA 2005;102:3738–3743.
38 Chang HY, Sneddon JB, Alizadeh AA, Sood R, 
West RB, Montgomery K, Chi JT, van de Rijn M, 
Botstein D, Brown PO: Gene expression signa-
ture of fibroblast serum response predicts human 
cancer progression: Similarities between tumors 
and wounds. PLoS Biol 2004;2:E7.
39 Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, 
Baehner FL, Walker MG, Watson D, Park T, 
Hiller W, Fisher ER, Wickerham DL, Bryant J, 
Wolmark N: A multigene assay to predict recur-
rence of tamoxifen-treated, node-negative breast 
cancer. N Engl J Med 2004;351:2817–2826.
40 Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, 
Livasy C, Carey LA, Reynolds E, Dressler L, 
Nobel A, Parker J, Ewend MG, Sawyer LR, 
Wu J, Liu Y, Nanda R, Tretiakova M, Ruiz 
Orrico A, Dreher D, Palazzo JP, Perreard L, 
Nelson E, Mone M, Hansen H, Mullins M, 
Quackenbush JF, Ellis MJ, Olopade OI, 
Bernard PS, Perou CM: The molecular portraits 
of breast tumors are conserved across microarray 
platforms. BMC Genomics 2006;7:96.
41 Ma XJ, Wang Z, Ryan PD, Isakoff SJ, 
Barmettler A, Fuller A, Muir B, Mohapatra G, 
Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, 
Amon P, Wang W, Enright E, Stecker K, 
Estepa-Sabal E, Smith B, Younger J, Balis U, 
Michaelson J, Bhan A, Habin K, Baer TM, 
Brugge J, Haber DA, Erlander MG, Sgroi DC: 
A two-gene expression ratio predicts clinical out-
come in breast cancer patients treated with tamoxi-
fen. Cancer Cell 2004;5:607–616.
42 Dupuy A, Simon RM: Critical review of published 
microarray studies for cancer outcome and guide-
lines on statistical analysis and reporting. J Natl 
Cancer Inst 2007;99:147–157.
43 Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, 
Smeds J, Nordgren H, Farmer P, Praz V, 
Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, 
Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, 
Bergh J, Piccart M, Delorenzi M: Gene expres-
sion profiling in breast cancer: Understanding the 
molecular basis of histologic grade to improve 
prognosis. J Natl Cancer Inst 2006;98:262–272.
44 Ioannidis JP: Microarrays and molecular research: 
Noise discovery? Lancet 2005;365:454–455.
45 Simon R, Radmacher MD, Dobbin K, McShane LM: 
Pitfalls in the use of DNA microarray data for 
diagnostic and prognostic classification. J Natl 
Cancer Inst 2003;95:14–18.
46 Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, 
Baker SC, Collins PJ, de Longueville F, Kawasaki ES, 
Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, 
Fischer GM, Tong W, Dragan YP, Dix DJ, 
Frueh FW, Goodsaid FM, Herman D, Jensen RV, 
Johnson CD, Lobenhofer EK, Puri RK, Schrf U, 
Thierry-Mieg J, Wang C, Wilson M, Wolber PK, 
Zhang L, Amur S, Bao W, Barbacioru CC, 
Lucas AB, Bertholet V, Boysen C, Bromley B, 
Brown D, Brunner A, Canales R, Cao XM, 
Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, 
Corson J, Corton JC, Croner LJ, Davies C, 
Davison TS, Delenstarr G, Deng X, Dorris D, 
Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, 
Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, 
Hager J, Haje PK, Han J, Han T, Harbottle HC, 
Harris SC, Hatchwell E, Hauser CA, Hester S, 
Hong H, Hurban P, Jackson SA, Ji H, Knight CR, 
Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, 
Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, 
McDaniel T, Mei N, Myklebost O, Ning B, 
Novoradovskaya N, Orr MS, Osborn TW, Papallo A, 
Patterson TA, Perkins RG, Peters EH, Peterson R, 
Philips KL, Pine PS, Pusztai L, Qian F, Ren H, 
Rosen M, Rosenzweig BA, Samaha RR, Schena M, 
Schroth GP, Shchegrova S, Smith DD, Staedtler F, 
Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, 
Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, 
Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, 
Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, 
Zhong S, Zong Y, Slikker W Jr: The microarray 
quality control (MAQC) project shows inter- and 
intraplatform reproducibility of gene expression 
measurements. Nat Biotechnol 2006;24:1151–1161.
47 Mackay A, Weigelt B, Grigoriadis A, Kreike B, 
Natrajan R, A’Hern R, Tan DS, Dowsett M, 
Ashworth A, Reis-Filho JS: Microarray-based class 
discovery for molecular classification of breast 
cancer: Analysis of interobserver agreement. J Natl 
Cancer Inst 2010;103:662–673.
48 He YD, Friend SH: Microarrays – the 21st century 
divining rod? Nat Med 2001;7:658–659.
49 Schena M: Microarray Analysis. Hoboken, Wiley-
Liss, 2003.
